Blue Owl Technology Finance Corp. will release its financial results for the third quarter ending September 30, 2026, on November 4 after market close. The company will host a webcast and conference call on November 5 at 11:30 a.m. Eastern Time to discuss the results. Blue Owl focuses on debt and equity investments in U.S. technology companies, especially software, with a portfolio valued at $14.7 billion as of June 30, 2026. Investors can access the call live via the company website or by phone, with a replay available for up to a year online.
Blue Owl Technology Finance Corp. is set to release its Q3 2026 financial results on November 4. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 02, 2026 02:31 WIB: Of 85 priced US Financials stocks, 36 rose and 48 fell. Notable movers include NU at USD 13.24 with a 1-day change of +4.62% and 90% buy order activity, SAN at USD 13.24 with -4.27% change and 96% buy order activity, and CLSK at USD 12.34 with -4.19% change and 100% buy order activity.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
